Secondary analysis of TASTE (492 of 680 analysed; perfusion-selected stroke ≤4.5 h): with M3-or-beyond occlusions, mRS 0–1 at 90 days was 77% with tenecteplase vs 63% with alteplase (aRR 1.23, 1.04–1.46); no significant interaction across occlusion sites (P=0.89).
Secondary analysisn = 492
Yogendrakumar et al. Tenecteplase Efficacy in Patients With Distal Occlusions: Secondary Analysis of the TASTE Randomized Clinical Trial